Fasting Insulin

Fasting insulin is one of the most underutilized, and most misread, tests in metabolic health. Most people who have had it measured were told their result was "normal." Many of those people had insulin resistance. While the Lipoprotein Insulin Resistance (LP-IR) Score is more predictive of future incident diabetes, fasting insulin can be a very useful tool to measure and manage metabolic health.

The problem is a fundamental disconnect between what standard lab reference ranges represent and what metabolic health actually requires. Understanding that gap is where fasting insulin testing becomes genuinely useful.

What Is Fasting Insulin?

Fasting insulin is a blood test that measures the concentration of insulin in the bloodstream after an overnight fast, typically 8–12 hours without caloric intake. It reflects the baseline level of insulin your pancreas is secreting to maintain blood glucose at rest.

Insulin is produced by pancreatic beta cells in response to rising blood glucose. Its primary role is to signal cells, particularly muscle, fat, and liver cells, to take up glucose from the bloodstream. When cells become resistant to that signal, the pancreas compensates by producing more insulin to achieve the same effect. The result is elevated fasting insulin alongside normal fasting glucose. This is a state called compensatory hyperinsulinemia.

Fasting insulin can identify this compensatory phase before fasting glucose, A1c, or standard lipid panels become abnormal.

Why Measure Fasting Insulin?

Standard metabolic screening, fasting glucose, A1c, and a basic lipid panel, can appear entirely normal in the early stages of insulin resistance. The pancreas is capable of compensating for years, sometimes decades, before glucose regulation begins to fail.

During that compensatory period, elevated insulin is doing significant downstream harm:

  • Driving atherogenic lipoprotein changes (higher VLDL, smaller LDL particles, lower HDL)

  • Promoting inflammation

  • Accelerating atherosclerosis

  • Contributing to hypertension through sodium retention and sympathetic nervous system activation

  • Stimulating abnormal cell growth pathways

Catching elevated fasting insulin early, before glucose dysregulation appears, is one of the clearest opportunities for meaningful prevention.

What Is a Normal Fasting Insulin Level?

This is where most people get misled. The reference range printed on a standard lab report represents the statistical distribution of the population tested, not a clinically optimal target.

Standard lab reference range (LabCorp): 2.6–24.9 µIU/mL

A result anywhere in this range will be reported as "normal." But a fasting insulin of 22 µIU/mL reflects significant insulin resistance. The population used to establish these ranges includes many individuals who are themselves insulin resistant which inflates the upper boundary well beyond what is metabolically healthy.

Functional and metabolic medicine practitioners use considerably tighter targets:

Fasting Insulin (µIU/mL) Interpretation
< 5 Optimal insulin sensitivity
5–9 Acceptable
10–14 Elevated — consistent with early insulin resistance
15–20 Significant insulin resistance
> 20 Marked insulin resistance
Note on lab reference ranges: Standard lab reports (LabCorp reference range: 2.6–24.9 µIU/mL) will flag values anywhere in this range as "normal." The thresholds above reflect functional and metabolic medicine targets, which are considerably tighter. A result of 20 µIU/mL will read as normal on a standard report but reflects marked insulin resistance by the criteria above.

These thresholds are not universally standardized. Different practitioners and institutions use slightly different cutoffs, which is one of fasting insulin's core limitations as a standalone test. Clinical context, trends over time, and corroborating markers matter as much as any single value.

What Does High Fasting Insulin Mean?

Elevated fasting insulin means the pancreas is working harder than it should to maintain normal blood glucose. It is the metabolic fingerprint of insulin resistance indicating that the cells are not responding to insulin's signal efficiently, so more insulin is required to do the same job.

Conditions associated with chronic hyperinsulinemia include:

  • Metabolic syndrome

  • Prediabetes and type 2 diabetes

  • Atherosclerotic cardiovascular disease (ASCVD)

  • Nonalcoholic fatty liver disease (NAFLD/MASLD)

  • Polycystic ovary syndrome (PCOS)

  • Hypertension

  • Certain hormone-sensitive cancers

Importantly, a person can have a fasting glucose in the normal range, even with a low-normal A1c, and still have significantly elevated fasting insulin. The glucose appears normal because the elevated insulin is successfully keeping it there. But the insulin level itself signals ongoing metabolic dysfunction.

Fasting insulin is most meaningful when interpreted alongside more stable insulin resistance markers or when more predictive biomarkers like the LP-IR Score are not available.

Our current Cardiometabolic Risk Assessment includes the LP-IR score instead as a more reproducible, lipoprotein-based measure of insulin resistance as part of a full cardiometabolic panel.

Learn why LP-IR outperforms fasting insulin → 

Order a Cardiometabolic Risk Assessment →

Limitations of Fasting Insulin Testing

Fasting insulin is a useful but imperfect test. Understanding its limitations is essential for proper interpretation.

Day-to-day biological variability. Fasting insulin can fluctuate by 20–40% or more between measurements, even under identical conditions. Stress, poor sleep, acute illness, and timing of the most recent meal all influence results. Many clinicians recommend averaging two or three measurements taken on separate days before drawing conclusions.

No standardized reference ranges. Unlike glucose or hemoglobin A1c, which have universal diagnostic thresholds, fasting insulin reference ranges vary meaningfully between laboratories and between countries. A "normal" reading at one lab may reflect a population baseline that includes significant metabolic dysfunction.

Assay variability between laboratories. Fasting insulin assays are not standardized across platforms. The same blood sample measured on different instruments can produce meaningfully different numerical results.

Fasting requirement. An 8–12 hour fast is required. Non-fasting results are clinically uninterpretable for insulin resistance assessment.

Cannot detect non-fasting insulin dynamics. Fasting insulin only captures the baseline state. Post-meal (postprandial) insulin patterns, which reveal insulin secretion and resistance dynamics in response to food, require a more complex insulin response test that is rarely performed outside of research settings.

These limitations are why fasting insulin is best used as a screening signal and directional indicator, interpreted alongside other markers, particularly HOMA-IR and the LP-IR score.

Fasting Insulin vs. LP-IR

Both fasting insulin and LP-IR assess insulin resistance, but they measure it from fundamentally different angles.

Fasting insulin measures insulin concentration at a single point in time. LP-IR measures the downstream metabolic pattern that chronic insulin resistance creates in lipoprotein particles which are a more stable composite signal that reflects chronic metabolic state rather than a moment-in-time reading.

The practical result: LP-IR has considerably lower day-to-day variability, is less affected by acute stressors, and connects insulin resistance more directly to cardiovascular risk through its lipoprotein components.

→ See our full comparison: Why LP-IR Outperforms Fasting Insulin for Insulin Resistance Assessment

→ LP-IR Score: What It Is, Normal Range & What It Means

Fasting Insulin vs. HOMA-IR

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a calculated index that combines fasting insulin with fasting glucose in a formula that partially corrects for the glucose-insulin relationship.

Compared to fasting insulin alone, HOMA-IR is generally considered more accurate because it accounts for the fact that insulin resistance affects both insulin secretion and glucose regulation simultaneously. A high fasting insulin reading is more meaningful if blood glucose is also elevated; HOMA-IR captures this interaction.

For most clinical purposes, if you are measuring fasting insulin, it is worth calculating HOMA-IR simultaneously since the incremental cost is zero since fasting glucose is required anyway.

→ HOMA-IR: What It Is, Formula, Normal Range & What It Means

Who Should Get a Fasting Insulin Test?

Fasting insulin is most informative for:

  • Adults with risk factors for insulin resistance: abdominal obesity, high triglycerides, low HDL, elevated blood pressure, family history of type 2 diabetes

  • People with normal fasting glucose or A1c who suspect early metabolic dysfunction

  • Individuals with PCOS, NAFLD, or other conditions strongly linked to insulin resistance

  • Anyone seeking a complete cardiometabolic risk picture beyond a standard lipid panel

  • People monitoring the metabolic response to lifestyle changes, dietary interventions, or pharmacological treatment

Fasting insulin is less useful as an isolated test. Its value increases substantially when interpreted alongside fasting glucose (for HOMA-IR), an NMR LipoProfile (for LP-IR and LDL-P), and other metabolic markers.

How to Lower Fasting Insulin

Fasting insulin is highly responsive to metabolic interventions:

Dietary:

  • Reduce refined carbohydrates and added sugars, which drive acute and chronic insulin secretion

  • Adopt time-restricted eating or intermittent fasting patterns that allow insulin to fall during fasting periods

  • Increase dietary fiber and whole food sources that moderate postprandial insulin response

  • Reduce ultra-processed food consumption

Physical activity:

  • Resistance training improves skeletal muscle insulin sensitivity which is the primary site of glucose disposal

  • Aerobic exercise increases insulin sensitivity acutely and chronically

  • Even modest daily walking (7,000–10,000 steps) improves fasting insulin in sedentary individuals

Sleep and stress:

  • Poor sleep acutely elevates insulin resistance; chronic sleep deprivation drives sustained hyperinsulinemia

  • Chronic psychological stress elevates cortisol, which drives glucose release and insulin secretion

Pharmacological (when indicated):

  • Metformin reduces hepatic glucose production, lowering the insulin demand required to maintain normal glucose

  • GLP-1 receptor agonists improve insulin sensitivity and reduce fasting insulin

  • SGLT2 inhibitors lower glucose and reduce insulin requirements through urinary glucose excretion

Frequently Asked Questions About Fasting Insulin

  • Standard lab reference ranges (typically 2.6–24.9 µIU/mL at LabCorp) reflect population distribution, not metabolic optimum. Most metabolic health practitioners consider fasting insulin below 5 µIU/mL as optimal, 5–9 µIU/mL as acceptable, and values at or above 10 µIU/mL as consistent with early insulin resistance, regardless of what the lab report says about "normal."

  • Yes, in two ways. First, standard "normal" ranges are set too wide. A result of 20 µIU/mL will read as normal on most lab reports but reflects significant insulin resistance. Second, insulin resistance can present in tissues (muscle, fat, liver) with different sensitivities, and fasting insulin captures only one dimension of that picture. Tests like LP-IR and HOMA-IR can provide additional perspective.

  • An 8–12 hour fast is required. Water is permitted. Any caloric intake, including black coffee with added fat, a supplement with caloric content, or gum, an stimulate insulin secretion and alter the result. The test is typically drawn in the morning after an overnight fast.

  • Yes, significantly. Fasting insulin can fluctuate 20–40% or more between measurements on consecutive days, even under controlled conditions. Stress, illness, poor sleep, and the timing and composition of the prior day's meals all influence the result. This variability is one of the key limitations of fasting insulin compared to more stable composite measures like LP-IR.

  • Fasting glucose measures blood sugar concentration after a fast. Fasting insulin measures insulin concentration. In early insulin resistance, fasting glucose can remain entirely normal while fasting insulin is already significantly elevated because the pancreas is compensating. Measuring both together (and calculating HOMA-IR) provides more diagnostic information than either alone.

  • Not exactly. Fasting insulin is one component of insulin resistance assessment, but it is not a direct measure of insulin resistance. The gold standard for measuring insulin resistance is the hyperinsulinemic-euglycemic clamp, a complex research protocol rarely used clinically. Fasting insulin, HOMA-IR, and LP-IR are all practical proxies, each with different strengths, limitations, and appropriate use cases.

  • No. Elevated fasting insulin typically reflects insulin resistance, the precursor to type 2 diabetes, not diabetes itself. In the compensatory hyperinsulinemia phase, the pancreas is still producing enough insulin to keep blood glucose in the normal range. Elevated fasting insulin is an early warning sign, not a diagnosis.

  • No. Fasting insulin is not included in standard metabolic or lipid panels and must be ordered specifically. Precision Health Reports' current Cardiometabolic Risk Assessment includes the LP-IR score as a more stable, NMR-derived measure of insulin resistance, rather than fasting insulin directly. A version of the assessment incorporating HOMA-IR is in development.

REFERENCES

Crofts CAP, et al. Hyperinsulinemia: A unifying theory of chronic disease? Diabesity. 2015;1(4):34–43. https://doi.org/10.15562/diabesity.2015.19

Reaven GM. Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607. PMID: 3056758

Després JP, Lamarche B, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334(15):952–957. PMID: 8596596

Shalaurova I, et al. Lipoprotein Insulin Resistance Index: A Lipoprotein Particle–Derived Measure of Insulin Resistance. Metab Syndr Relat Disord. 2014;12(8):455–461. PMC4175429

Matthews DR, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419. PMID: 3899825